Monitor for a prospectus supplement that would disclose actual offering size, terms, and use of proceeds. The strong cash position and recent Gilead deal suggest any future draw would likely be opportunistic rather than forced. The activist stake reduction and upcoming Phase 3 ECLIPSE 1 data in Q4 2026 are key catalysts to watch.
VIR drugs
VIR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $9.96entry
- T+1 · 18h ago −3.82%α −1.90% · $9.58
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vir Biotechnology filed an automatic shelf registration (S-3ASR) to register an unlimited amount of senior and subordinated debt securities for future issuance. The filing does not specify any immediate offering size, pricing, or use of proceeds. The company has $901.3M in cash and investments as of September 30, 2026, and recently entered a Gilead collaboration worth up to $1.74B in milestones, suggesting this shelf is opportunistic rather than a distress-driven capital raise. The filing follows a recent activist stake reduction by ARCH Venture Fund and a Q3 2026 earnings report showing a narrowed net loss.
Key Facts
- S-3ASR filed registering an unlimited amount of senior and subordinated debt securities
- No specific offering size, pricing, or use of proceeds stated in the filing
- Company had $901.3M in cash and investments as of September 30, 2026
- Q3 2026 net loss of $96.3M ($0.57 per share), narrowed from $163.1M in Q3 2025
- Gilead collaboration announced with up to $1.74B in milestones
- ARCH Venture Fund reduced stake from 7.4% to 6.9% on November 3-5, 2026
- Short interest at 16.9M shares (~9.9% of estimated shares outstanding) as of October 30, 2026
Financial Impact
No offering size or pricing specified; shelf registers an unlimited principal amount of debt securities
Risk Factors
- Potential future debt issuance could increase leverage and interest expense
- Convertible debt issuance could create dilution upon conversion
- Company remains unprofitable with ongoing operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3ASR Filing (Primary) | 0001193125-26-458278 |
| Document: d187683dex43.htm | 0001193125-26-458278 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry $9.84 Now $9.58 +2.64% settles Nov 23
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Viewing Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers